In an article entitled "Bill C-442: Shining the limelight on the Lyme-like?" published last week in the Journal of Infectious Diseases & Medical Microbiology, two Canadian physicians express both their support and reservations regarding the bill that has already passed the House of Commons. An Act Respecting a Federal Framework on Lyme Disease, introduced by Member of Parliament Elizabeth May, now awaits a second reading in the Senate. In the interim, Dr. Kevin Laupland and Dr. Louis Valiquette have shared some concerns, which are worthy of addressing. "While we will hope for improvements in the diagnosis of Lyme disease, we are skeptical that major advances will arise as a result of Bill C-442. Accordingly, we believe that a sizable cohort of patients with chronic Lyme-like disease will remain," writes the authors.
I recently read an article in The New York Times that really spoke to me and would apply to so many of my own patients. “When the Diagnosis Is Rare, Parents May Know More Than Professionals,” by David Wheeler, highlights a family who struggles to find answers to their young child’s medical condition. For two years, the parents researched her symptoms, pursued different physicians and became her strongest advocate. Eventually, their child was diagnosed with a rare disease, Infantile Neuroaxonal Dystrophy (INAD).
The US Food and Drug Administration (FDA) is pushing to regulate (or eliminate altogether) laboratory developed tests (LDT).  Diagnostic tests for Lyme disease will be targeted, initially, as the FDA begins to phase in its oversight.
A read of the Infectious Diseases Society of America (IDSA) 2006 evidence-based guidelines would lead you to believe that for Lyme disease one size fits all. All you need is a single 200 mg dose of doxycycline for a tick bite; a single 10 to 21 days of antibiotics for Lyme disease; but no retreatment.
If you have been disappointed to find your fibromyalgia patient is not getting better, you may conclude your patient is a candidate for Lyme disease treatment. The medical conditions share similar symptoms, making an accurate diagnosis challenging.
The house bill, Amended HR 4701, titled "To provide for scientific frameworks with respect to vector borne diseases," September 9, 2014 passed the evening of September 9, 2014. Click on read more for a link to the C-span coverage.
There is growing evidence that Lyme disease can lead to psychiatric symptoms, including anxiety disorders and depression. There have been cases where chronically ill Lyme disease patients were suicidal. But, whether psychiatric manifestations, including suicidal ideation, are due to an infection or the result of struggling with a debilitating condition is unknown.
Labcorp will not offer a western blot test for individuals unless they are positive or equivocal for the Enzyme Immunoassay (EIA) or Immunoflorescense (IFA) screening tests for Lyme disease as of August 11, 2014.
Dr. Daniel Cameron, MD, MPH, is a nationally recognized leader for his expertise in the diagnosis and treatment of Lyme disease and other tick-borne illnesses. For more than 30 years, he has been treating adolescents and adults suffering from Lyme disease.